BMS 986158
Alternative Names: BET inhibitor - Bristol-Myers Squibb; BMS-986158Latest Information Update: 12 Feb 2025
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Indoles; Propanols; Pyridines; Small molecules; Triazoles
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Multiple myeloma; Myelofibrosis
Most Recent Events
- 07 Dec 2024 Updated efficacy and adverse event data from a phase I/II trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 27 Mar 2024 Efficacy and pharmacokinetics data from a phase I/II in Myelofibrosis presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2024)